Valneva Reports Profitable Quarter Amid Vaccine Launches
Company Announcements

Valneva Reports Profitable Quarter Amid Vaccine Launches

Valneva (VALN) has released an update.

Valneva SE has reported €116.6 million in total revenues for the first nine months of 2024, with a notable turnaround to a €24.7 million net profit, driven by strong product sales and a successful private placement. The company is progressing with the launch of its chikungunya vaccine in Canada and Europe, and anticipates further approvals in Brazil and the UK. With a promising pipeline, including the S4V2 Shigella vaccine candidate, Valneva is poised for growth and strategic expansion.

For further insights into VALN stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskValneva SE Reports Profitable Nine-Month Performance
TipRanks Auto-Generated NewsdeskValneva’s Chikungunya Vaccine Gains Scientific Spotlight
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App